Procept BioRobotics Corp. (PRCT) intrinsic value & 10-year financials
Procept BioRobotics Corp. (PRCT) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue grew 109.0% a year to $308.1M, with an average return on invested capital of -77.9%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $17.57
- Market cap
- $975.9M
- Revenue (FY2025)
- $308.1M
- Revenue growth (7-yr CAGR)
- 109.0%
- ROIC (10-yr avg)
- -77.9%
- Free cash flow (FY2025)
- -$58.3M
PRCT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $308.1M | -$95.6M | -$1.72 | -$58.3M | -33.7% | -68.7% |
| FY2024 | $224.5M | -$91.4M | -$1.75 | -$103.6M | -43.0% | -78.0% |
| FY2023 | $136.2M | -$105.9M | -$2.24 | -$133.2M | -80.2% | -144.2% |
| FY2022 | $75.0M | -$87.2M | -$1.96 | -$83.0M | -107.6% | -247.7% |
| FY2021 | $34.5M | -$59.9M | -$3.63 | -$57.9M | -157.1% | 50.3% |
| FY2020 | $7.7M | -$53.0M | -$14.47 | -$48.6M | -619.4% | 20.8% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
PROCEPT BioRobotics Corp revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
PROCEPT BioRobotics Corp has historically struggled to out-earn its cost of capital, averaging just -37.0% ROIC.
PROCEPT BioRobotics Corp capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, PROCEPT BioRobotics Corp is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-57.13 per share.